RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer

1Ferroptosis emerging as a new programmed cell death is form, which is genetically, biochemically, and morphologically distinct from necrosis, autophagy, and apoptosis. This process is characterized by suppression of the phospholipid glutathione peroxidase 4 (GPX4) and subsequent intracellular accumulation of lipid reactive oxygen species (ROS) in an iron-dependent manner. Ferroptosis can be induced by some small molecules, including erastin and RSL3. Erastin can activate ferroptosis by directly suppressing the cell surface cysteine-glutamate antiporter (system Xc-), resulting in the inactivation of the cellular antioxidant glutathione (GSH). Whereas, RSL3 is identified as a potent ferroptosis-triggering agent, which is dependent on the activity of GPX4. GPX4, as a negative target of RSL3, is demonstrated to mediate suppression of ferroptosis. In addition, several genes or proteins have been also involved in the process of ferroptosis. Ras transformation is demonstrated to render cells sensitive to ROS-induced ferroptosis; however, in some cases RAS-driven nuclear factor erythroid 2-related factor 2 (NRF2) activation can enhance the expression of antioxidant genes that protects hepatocellular carcinoma (HCC) cells against ferroptosis. Meanwhile, p53 contributes to ROS-induced ferroptosis by transcriptional repression of solute carrier family 7 member 11 (SLC7A11). Although a number of key targets has been demonstrated to be the important mediators that induce ferroptosis, it still unclear whether these targets are susceptible to ferroptosis-induced cell death.

2In cancer cells, erastin or RSL3 can promote ferroptosis-induced cell death. However, ferroptosis has not been investigated directly in cancer therapy. Therefore, exploitation of ferroptosis for killing cancer cells in response to specific compounds are attracting more and more attention in cancer therapy. We investigated the effect of RSL3 (a selective ferroptosis inducer) on the viability of three different CRC cells and found RSL3 triggered ferroptotic cell death in a dose- and time-dependent manner, which was due to increased ROS levels and an increase in the cellular labile iron pool. In further analysis, we demonstrated that GPX4 inhibition was a key determinant in RSL3-induced ferroptosis. Overexpression GPX4 rescued the ferroptotic cell death induced by RSL3 treatment. Our results provide a promising strategy to for the treatment of colorectal cancer (CRC) patients.

3Human CRC cell lines (HCT116, LoVo, HT29) were purchased from ATCC, these cells were cultured in McCoy’s 5A or Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, Rockville, MD, United States) with 10% heat-inactivated fetal bovine serum at 37°C, 95% humidity, and 5% CO2. The fetal bovine serum was purchased from Corille (184590, Australia). RSL3 (#S8155) and liproxstatin-1(#S7699) and ferrostatin-1 (#S7243) were purchased from Selleck Chemical (Houston, TX, United States). Z-VAD-FMK (#V116), deferoxamine (#D9533), necrostatin-1 (#N9037), chloroquine (#C6628), and doxorubicin (#D1515) were obtained from Sigma. Ferritin (ab75973), transferrin (ab82411) and GPX4 (ab125066) were purchased form Abcam; GAPDH (#5174) was obtained from Cell Signaling Technology (CST). GPX4 plasmid (RG208065) was purchased from OriGene.

4Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8) (LJ621, Dojindo, Japan) according to the manufacturer’s instructions. Cells were seeded in 96-well flat bottom microtiter plates at a density of 5,000 cells per well. Twenty-four hours later, RSL3 was added at the concentrations indicated for 6, 12, 24, and 48 h. The absorbance was measured on a microplate reader (Synergy HT, Bio-Tek, United States) at 450 nm.

5Pharmingen annexin V-FITC Apoptosis Detection Kit I (BD, United States) was used to detect apoptosis and the estimation procedure was performed according to the manufacturer’s instructions.106 cells were seeded into a 6 cm dish. After attachment overnight, cells were washed twice with PBS and the medium was replaced medium with 3 μM RSL3 (or combination with 1 μM liproxstatin-1) for 24 h. All cells including the floating cells in the culture medium were harvested. Cell were washed, trypsinized, and pelletized together with the supernatant by centrifugation. After repeated washing, the cells were resuspended in ice-cold 1× binding buffer at a concentration of 1 × 106 cells/ml. 100 μl of cell suspension were each mixed with 5 μl FITC annexin V and 5 μl PI. The mixture was incubated for 15 min at room temperature in the dark and then analyzed by FACS Calibur Flow Cytometer (Beckman Coulter, CytoFLEX S, United States).

6Labile iron pool (LIP) was measured according to the methods described by the manufacturer’s instructions. Briefly, cells were trypsinized, washed twice with 0.5 ml of PBS, and incubated at a density of 1 × 106/ml for 15 min at 37°C with 0.05 μM calcein-acetoxymethyl ester (AnaSpec). Then, the cells were washed twice with 0.5 ml of PBS and either incubated with deferiprone (100 μM) for 1 h at 37°C or left untreated. The cells were analyzed with a flow cytometer. Calcein was excited at 488 nm, and fluorescence was measured at 525 nm. The difference in the cellular mean fluorescence with and without deferiprone incubation reflects the amount of LIP.

7Change in intracellular ROS levels were by measuring the oxidative conversion of cell permeable 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Sigma) to fluorospectro-photometer. Cells were plated in 6 cm dish (1 × 106 cells/well) and allowed to attach overnight. Cells were incubated with control media or RSL3 for 24 h. The cells were washed with D-Hank’s and incubated with DCFH-DA at 37°C for 20 min. Then DCF fluorescence distribution of 20,000 cells was detected by FACS Calibur Flow Cytometer (Beckman Coulter, CytoFLEX S, United States) at an excitation wavelength of 488 nm and at an emission wavelength of 535 nm.

8Human CRC cell lines (HCT116, LoVo, HT29) were transiently transfected with GPX4-expressing plasmid or empty vector for 36 h, using MegaTran 1.0 transfection reagent (OriGene). Then, cells were harvested for further study.

9Cells were harvested from cultured dishes and were lysed in a lysis buffer [20 mM Tris-HCl pH 7.6, 1 mM EDTA, 140 mM NaCl, 1% NP-40, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium vanadate]. Protein concentration was determined using a BCA Protein Assay Kit (P0009, Beyotime). Cell lysates (40 mg protein/line) were separated on a 5–20% Tris-Tricine Ready Gel SDSPAGE (Bio-Rad) for nitrocellulose membrane blotting. The blotted membranes were blocked with 5% skim milk for 1 h and were incubated with primary antibodies. The immunoreactive bands were visualized by enhanced chemiluminescence using horseradish perox-idase-conjugated IgG secondary antibodies. Band density was measured by densitometry, quantified using gel plotting macros of NIH image 1.62, and normalized to an indicated sample in the identical membrane.

10Data are expressed as means ± SD of three independent experiments. Statistical analysis was performed using Prism 7.0c GraphPad Software. The significance of differences between groups was determined using t-test. A p-value < 0.05 was considered statistically significant.

11RSL3 (RAS-selective lethal) is a ferroptosis-inducing agent. The previous reports showed RSL3 could kill RAS-transformed tumorigenic fibroblast cell lines and irreversibly inactivate GPX4. To identify whether RSL3 induces growth suppression in CRC cells, three human colorectal cell lines were treated with various concentrations of RSL3 at different times and the cell viability was assessed by the Cell Counting Kit-8 (CCK-8). We found RSL induced cell death in CRC cells in dose- and time-dependent manner (Figure 1). The 24 h IC50 of RSL3 for HCT116, LoVo, and HT29 was 4.084 μM, 2.75 μM, and 12.38 μM, respectively. Consequently, we used 3 μM RSL3 in HCT116, LoVo, and HT29 cells for 24 h in subsequent experiments. Interestingly, RSL3 induced growth inhibition not only in K-ras mutant HCT116 and LoVo cells but also in K-ras wild type HT29 cell. Therefore, RAS mutation status appeared to have no impact on the cell viability of CRC cells after RSL3 treatment. Taken together, our results suggest that RSL3 selectively induces growth inhibition in CRC cells in dose- and time-dependent manner but not RAS-dependent manner.

12To assess whether ferroptosis contributed to the growth inhibition to RSL3 in CRC cells, we treated these cells with liproxstatin-1 (Lip-1). Lip-1, a potent pharmacological inhibitor of ferroptosis, is demonstrated to suppress ferroptosis via lipid peroxide scavenging in an inducible mouse model of GPX4 depletion as well as in immortalized fibroblasts in the absence of GPX4. Then, cell death was assessed by flow cytometry. As shown in Figures 2A,B, three CRC cells displayed extensive percentage of dead cells after RSL3 and pre-treatment of these cells with the ferroptosis inhibitor Lip-1 rescued RSL3-induced cell death.

13To further determine the role of in RSL3-induced cell death, HCT116, LoVo, and HT29 cells were treated with RSL3 in the absence or presence of several cell death inhibitors. The treatment combined with deferoxamine (an iron-chelating agent), ferrostatin-1 (a potent inhibitor of ferroptosis), but not with necrostatin-1 (a potent inhibitor of necroptosis), chloroquine (a potent inhibitor of autophagy) or Z-VAD-FMK (a general caspase inhibitor), prevented RSL3-induced growth inhibition in these cells (Figure 3). Thus, these data indicate that ferroptosis may contributes to RSL3-induced growth inhibition in CRC cells.

14Iron is the essential reactive element for many biological processes including ROS generation reaction and ferroptosis. Moreover, the LIP, as the crossroad of cellular iron traffic, was reported to be associated with ferroptosis by directly catalyzing ROS generation. We first detected the cellular LIP. RSL3 treatment triggered an increase of the cellular LIP (Figure 4A). Then, we measured if suppression of ferroptosis can block RSL3-induced LIP increase. As shown in Figure 4A, Lip-1 can block ferroptosis-associated LIP increase.

15Reactive oxygen species accumulation is regarded as one hallmark of ferroptosis. Increasing data show that various ROS scavengers and ferroptosis inhibitors can entirely repress ferroptotic cell death and cellular ROS accumulation. To determine whether ROS played a key role in RSL3-induced cell death, we measured intracellular ROS levels by using an oxidation-sensitive fluorescent probe DCFH-DA, which is oxidized to DCF in the presence of ROS. Our results showed RSL-3 increased intracellular ROS levels which was represented by the DCF intensity (Figures 4B,C). Moreover, this effect can be rescued by the treatment with Lip-1 (Figures 4B,C). In summary, these data suggest RSL3 promotes ferroptosis-associated LIP increase and ROS accumulation.

16GPX4 is one of the most important antioxidant enzymes and an essential regulator of ferroptotic cancer cell death. The current studies have showed that the activation of GPX4 can suppress ferroptosis and inflammation. As agreement with these reports, our study showed RSL-3 could inhibit GPX4 expression and this may subsequently have a critical role in RSL-3-induced ferroptosis (Figure 5A). Moreover, overexpression GPX4 resulted in decreased cell death after RSL3 treatment (Figures 5B,C). Therefore, GPX4 inhibition could be a key determinant in RSL3-induced ferroptosis.

17As we know, the ROS generation LIP rise could be attributed to either the degradation of cellular iron storage protein ferritin or the accumulation of iron uptake. Transferrin-mediated iron transport into cells is the most common iron uptake pathway, and transferrin is a key regulator for ferroptosis. To investigate whether iron regulatory proteins such as ferritin and transferrin are changed after RSL-3 treatment, we performed Western blotting analysis to determine the expression of iron regulatory proteins. The expression of transferrin significantly increased after RSL-3 treatment (Figure 5A). To make sure this effect was not attributed to the alteration in iron transport regulatory proteins, we detected the expression of transferrin receptor ferritin and found that transferrin was not significantly changes after RSL-3 treatment (Figure 5A). Our results suggest RSL3 treatment triggers ferroptotic cell death in CRC cells through altering iron transport.

18Ferroptosis is dependent upon intracellular iron, and is a new cell death form distinct from necrosis, autophagy, and apoptosis. Ferroptosis is tightly controlled by GPX4 and some iron transport regulatory proteins. Exploitation of ferroptosis for killing cancer cells in response to specific compounds are attracting more and more attention in cancer therapy. The ferroptosis trigger erastin can overcome the drug resistance of chemotherapeutic agents in acute myeloid leukemia cells. Sorafenib is shown to induce ferroptosis in iron-dependent oxidative mechanisms, which open new avenues for the optimization of clinical application of sorafenib in the treatment for HCC. Artesunate (ART), an anti-malarial, induces an iron- and ROS-dependent cell killing in pancreatic ductal adenocarcinoma cell lines with wild-type and mutant K-Ras, which indicates ART can function as a specific inducer of ferroptosis in pancreatic cancer cells. However, the role of ferroptosis in CRC is still unclear.

19In this study, we for the first time reported RSL3 triggered ferroptotic cell death by promoting the accumulation of cellular ROS and increasing the cellular LIP level. Mechanismly, we found transferrin expression were elevated in CRC cells treated with RSL3 accompanied by a decrease in the expression of GPX4, indicating an iron-dependent cell death. Moreover, overexpression GPX4 rescued the ferroptotic cell death induced by RSL3 treatment, indicating that GPX4 inhibition could be a key determinant in RSL3-induced ferroptosis in CRC cells. Our results may provide a pervasive and dynamic form of cell death for CRC treatment, however, this study is lack of sufficient experimental evidence to support our conclusions and this research is based on in vitro findings, which do not always extrapolate to the in vivo setting. In the future, we will make further investigations for this limitations.

20XS, TX, and HL conceived the idea and designed the study. RZ and XS performed all the experiments, analyzed the data, and co-wrote the paper. TD, LZ, MZ, XmH, YX, and XxH provided technical support. SL helped correcting the manuscript. All the authors read and approved the final version of the manuscript prior to submission.

21The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.